Compare KRRO & NVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRRO | NVX |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | United States | Australia |
| Employees | N/A | 192 |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 150.0M | 144.3M |
| IPO Year | 2019 | N/A |
| Metric | KRRO | NVX |
|---|---|---|
| Price | $11.21 | $0.58 |
| Analyst Decision | Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $34.80 | N/A |
| AVG Volume (30 Days) | 122.0K | ★ 308.4K |
| Earning Date | 05-13-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,392,000.00 | N/A |
| Revenue This Year | N/A | $3,904.19 |
| Revenue Next Year | N/A | $91.72 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 181.46 | N/A |
| 52 Week Low | $5.20 | $0.59 |
| 52 Week High | $55.89 | $3.86 |
| Indicator | KRRO | NVX |
|---|---|---|
| Relative Strength Index (RSI) | 46.11 | 32.65 |
| Support Level | $10.81 | N/A |
| Resistance Level | $14.42 | $0.75 |
| Average True Range (ATR) | 0.99 | 0.05 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 42.92 | 13.62 |
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.
NOVONIX Ltd is a battery technology company developing and scaling materials and equipment critical to the lithium-ion battery supply chain. The company has three operating segments: Battery Materials: It develops and manufactures battery anode materials, ii) Battery Technology: It develops and manufactures battery cell testing equipment, performs consulting services and carries out research and development in battery development, and Graphite Exploration: It manages the maintenance and future development of Mount Dromedary natural graphite deposit. The majority of the company's revenue is derived from the Battery Technology segment. Geographically, the maximum revenue is derived from North America, followed by Asia, and Europe.